Celon Pharma (WAR:CLN) EPS (Basic): zł2.04 (TTM As of Mar. 2026)


WAR:CLN Celon Pharma SA WAR:CLN
57 GF Score
Price zł19.52
GF Value zł22.51
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Celon Pharma EPS (Basic)?

Celon Pharma WAR:CLN -2.30% 57 EPS (Basic) is zł2.04 as of Mar. 2026. GuruFocus rates WAR:CLN with a GF Score™ of 57/100 and a GF Value™ of zł22.51 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Celon Pharma's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was zł3.06. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was zł2.04.

Celon Pharma's EPS (Diluted) for the three months ended in Mar. 2026 was zł3.06. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was zł2.03.

Celon Pharma's EPS without NRI for the three months ended in Mar. 2026 was zł3.06. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 2.03.

During the past 3 years, the average EPS without NRI Growth Rate was -22.60% per year. During the past 5 years, the average EPS without NRI Growth Rate was -90.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 11 years, Celon Pharma's highest 3-Year average EPS without NRI Growth Rate was -6.70% per year. The lowest was -193.80% per year. And the median was -32.40% per year.

Celon Pharma  (WAR:CLN) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Celon Pharma EPS (Basic) Related Terms

Celon Pharma EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Celon Pharma's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celon Pharma EPS (Basic) Chart

Celon Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.25 -0.77 -0.55 -0.64 -1.49

Celon Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.47 -0.61 0.07 -0.48 3.06
WAR:CLN
57GF Score
Celon Pharma SA WAR:CLN
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Celon Pharma EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Celon Pharma's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-79.363-0)/53.264
=-1.49

Celon Pharma's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(162.596-0)/53.136
=3.06

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł2.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of zł2.04 mean?
Celon Pharma (WAR:CLN) has a EPS (Basic) of zł2.04 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Celon Pharma and its competitors.
Is Celon Pharma's EPS (Basic) too high?
Celon Pharma's current EPS (Basic) is zł2.04. Overall, Celon Pharma has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Celon Pharma's EPS (Basic) compare to ZTS and UTHR?
Celon Pharma's EPS (Basic) of zł2.04 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Drug Manufacturers company?
A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Celon Pharma and its competitors. Celon Pharma's current EPS (Basic) is zł2.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celon Pharma stock overvalued right now?
Based on GuruFocus' analysis, Celon Pharma (WAR:CLN) is currently considered Modestly Undervalued. The stock's GF Value™ is zł22.51, compared to a current price of zł19.52 — trading 13.3% below its estimated fair value. The current EPS (Basic) is zł2.04. Celon Pharma's overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Celon Pharma (WAR:CLN), the current EPS (Basic) is zł2.04 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Celon Pharma (WAR:CLN) Overvalued in 2026?

Based on GuruFocus' analysis, Celon Pharma stock appears to be undervalued. The current stock price of zł19.52 is trading 13.3% below its estimated GF Value™ of zł22.51. GuruFocus considers Celon Pharma to be Modestly Undervalued.

Key valuation signals for WAR:CLN:

  • EPS (Basic): zł2.04
  • GF Value™: zł22.51 vs. price of zł19.52 (13.3% below fair value)
  • GF Score™: 57/100 with 3 warning signs

No single metric tells the full story. See the WAR:CLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Celon Pharma Business Description

Other Exchanges 8RP:Germany
Address Ogrodowa 2A, Kielpin, Lomianki, POL, 05-092
Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.
57GF Score

Get the complete analysis for WAR:CLN

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł19.52
Price
zł22.51
GF Value